美疾控中心疫苗顾问委员会通过延长停用强生新冠疫苗建议
美国疾控中心疫苗接种顾问委员会举行会议,通过延长暂停接种强生(JNJ.US)新冠疫苗的建议,直至下次会议为止。下次会议日期将於周五(16日)公布。会上委员讨论是否需要额外临床数据以作出决定,或押後接种是否令美国人面临感染新冠的风险。
美国为近700万人接种强生新冠疫苗,其後报告6宗血栓病例,患者为18至48岁女子,其中1人死亡,其余均须留在深切治疗部。有关个案均出现脑静脉窦血栓及血小板减少症。强生药物业务医疗总监Aran Maree在会上表示,疫苗与血栓个案关连未完成建立,但认同该等个案可代表接种有关疫苗的潜在风险。
6宗血栓个案中,3宗为肥胖症人士,5人初时出现头病徵状。另外,在临床测试中有1名25岁男子出现脑静脉窦血栓,但没有出现血小板减症。辉瑞及Moderna新冠疫苗临床测试均没有出现有关情况。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.